Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo

D. E. Hughes, K. R. Wright, H. L. Uy, A. Sasaki, T. Yoneda, G. David Roodman, G. R. Mundy, B. F. Boyce

Research output: Contribution to journalArticle

850 Citations (Scopus)

Abstract

Bisphosphonates inhibit bone resorption and are therapeutically effective in diseases of increased bone turnover, such as Paget's disease and hypercalcemia of malignancy. The mechanisms by which they act remain unclear. Proposed mechanisms include inhibition of osteoclast formation from precursors and inhibitory or toxic effects on mature osteoclasts. We have developed a new in vitro model to study osteoclast survival and in this paper present in vitro and in vivo evidence that may explain both the observed reduction in osteoclast numbers and in bone resorption by mature osteoclasts, namely that bispbosphonates induce programmed cell death (apoptosis). Three bisphosphonates (risedronate, pamidronate, and clodronate) caused a 4- to 24- fold increase in the proportion of osteoclasts showing the characteristic morphology of apoptosis in vitro. This observation was confirmed in vivo in normal mice, in mice with increased bone resorption, and in nude mice with osteolytic cancer metastases, with similar-fold increases to those observed in vitro. Of the three compounds, risedronate, the most potent inhibitor of bone resorption in vivo, was the strongest inducer of osteoclast apoptosis in vitro. Osteoclast apoptosis may therefore be a major mechanism whereby bisphosphonates reduce osteoclast numbers and activity, and induction of apoptosis could be a therapeutic goal for new antiosteoclast drugs.

Original languageEnglish (US)
Pages (from-to)1478-1487
Number of pages10
JournalJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Volume10
Issue number10
StatePublished - 1995
Externally publishedYes

Fingerprint

Diphosphonates
Osteoclasts
Apoptosis
Bone Resorption
pamidronate
Bone Density Conservation Agents
Clodronic Acid
In Vitro Techniques
Bone Remodeling
Poisons
Hypercalcemia
Nude Mice
Neoplasms
Cell Death
Neoplasm Metastasis

ASJC Scopus subject areas

  • Surgery

Cite this

Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. / Hughes, D. E.; Wright, K. R.; Uy, H. L.; Sasaki, A.; Yoneda, T.; Roodman, G. David; Mundy, G. R.; Boyce, B. F.

In: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, Vol. 10, No. 10, 1995, p. 1478-1487.

Research output: Contribution to journalArticle

Hughes, D. E. ; Wright, K. R. ; Uy, H. L. ; Sasaki, A. ; Yoneda, T. ; Roodman, G. David ; Mundy, G. R. ; Boyce, B. F. / Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. In: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 1995 ; Vol. 10, No. 10. pp. 1478-1487.
@article{968401380fbf4352ab8202f02c8f0989,
title = "Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo",
abstract = "Bisphosphonates inhibit bone resorption and are therapeutically effective in diseases of increased bone turnover, such as Paget's disease and hypercalcemia of malignancy. The mechanisms by which they act remain unclear. Proposed mechanisms include inhibition of osteoclast formation from precursors and inhibitory or toxic effects on mature osteoclasts. We have developed a new in vitro model to study osteoclast survival and in this paper present in vitro and in vivo evidence that may explain both the observed reduction in osteoclast numbers and in bone resorption by mature osteoclasts, namely that bispbosphonates induce programmed cell death (apoptosis). Three bisphosphonates (risedronate, pamidronate, and clodronate) caused a 4- to 24- fold increase in the proportion of osteoclasts showing the characteristic morphology of apoptosis in vitro. This observation was confirmed in vivo in normal mice, in mice with increased bone resorption, and in nude mice with osteolytic cancer metastases, with similar-fold increases to those observed in vitro. Of the three compounds, risedronate, the most potent inhibitor of bone resorption in vivo, was the strongest inducer of osteoclast apoptosis in vitro. Osteoclast apoptosis may therefore be a major mechanism whereby bisphosphonates reduce osteoclast numbers and activity, and induction of apoptosis could be a therapeutic goal for new antiosteoclast drugs.",
author = "Hughes, {D. E.} and Wright, {K. R.} and Uy, {H. L.} and A. Sasaki and T. Yoneda and Roodman, {G. David} and Mundy, {G. R.} and Boyce, {B. F.}",
year = "1995",
language = "English (US)",
volume = "10",
pages = "1478--1487",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo

AU - Hughes, D. E.

AU - Wright, K. R.

AU - Uy, H. L.

AU - Sasaki, A.

AU - Yoneda, T.

AU - Roodman, G. David

AU - Mundy, G. R.

AU - Boyce, B. F.

PY - 1995

Y1 - 1995

N2 - Bisphosphonates inhibit bone resorption and are therapeutically effective in diseases of increased bone turnover, such as Paget's disease and hypercalcemia of malignancy. The mechanisms by which they act remain unclear. Proposed mechanisms include inhibition of osteoclast formation from precursors and inhibitory or toxic effects on mature osteoclasts. We have developed a new in vitro model to study osteoclast survival and in this paper present in vitro and in vivo evidence that may explain both the observed reduction in osteoclast numbers and in bone resorption by mature osteoclasts, namely that bispbosphonates induce programmed cell death (apoptosis). Three bisphosphonates (risedronate, pamidronate, and clodronate) caused a 4- to 24- fold increase in the proportion of osteoclasts showing the characteristic morphology of apoptosis in vitro. This observation was confirmed in vivo in normal mice, in mice with increased bone resorption, and in nude mice with osteolytic cancer metastases, with similar-fold increases to those observed in vitro. Of the three compounds, risedronate, the most potent inhibitor of bone resorption in vivo, was the strongest inducer of osteoclast apoptosis in vitro. Osteoclast apoptosis may therefore be a major mechanism whereby bisphosphonates reduce osteoclast numbers and activity, and induction of apoptosis could be a therapeutic goal for new antiosteoclast drugs.

AB - Bisphosphonates inhibit bone resorption and are therapeutically effective in diseases of increased bone turnover, such as Paget's disease and hypercalcemia of malignancy. The mechanisms by which they act remain unclear. Proposed mechanisms include inhibition of osteoclast formation from precursors and inhibitory or toxic effects on mature osteoclasts. We have developed a new in vitro model to study osteoclast survival and in this paper present in vitro and in vivo evidence that may explain both the observed reduction in osteoclast numbers and in bone resorption by mature osteoclasts, namely that bispbosphonates induce programmed cell death (apoptosis). Three bisphosphonates (risedronate, pamidronate, and clodronate) caused a 4- to 24- fold increase in the proportion of osteoclasts showing the characteristic morphology of apoptosis in vitro. This observation was confirmed in vivo in normal mice, in mice with increased bone resorption, and in nude mice with osteolytic cancer metastases, with similar-fold increases to those observed in vitro. Of the three compounds, risedronate, the most potent inhibitor of bone resorption in vivo, was the strongest inducer of osteoclast apoptosis in vitro. Osteoclast apoptosis may therefore be a major mechanism whereby bisphosphonates reduce osteoclast numbers and activity, and induction of apoptosis could be a therapeutic goal for new antiosteoclast drugs.

UR - http://www.scopus.com/inward/record.url?scp=0029133135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029133135&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 1478

EP - 1487

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 10

ER -